表紙
市場調查報告書
商品編碼
659352

類鴉片物質的全球市場:各產品類型、應用、受體耦合、應用、地理的成長率,趨勢及預測(2018年∼2023年)

Opioids Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 125 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球類鴉片物質市場,預計從2018年到2023年的預測期間內,以約5.0%的年複合成長率成長。由罌粟可取得的類鴉片物質劑,大致區分為合法製造的醫藥品與違法的毒品。類鴉片物質市場,主要由於緩和照護的增加和疼痛管理的普及成長所促進。各地區中,因為類鴉片物質的引進增加,老年人口增加,美國及加拿大出色的醫療設施的需求增加,預計北美在預測期間支配市場。

本報告提供全球類鴉片物質市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要推論

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品及服務的威脅
    • 產業內的競爭

第6章 成長要素,阻礙因素,機會,課題分析(DROC)

  • 市場成長要素
    • 整形外科的疾病及慢性疼痛的流行
    • 從類鴉片物質的即時放出到持續放出性製劑
    • 學名藥製造商濫用防止劑(ADF)受到高度的關注
    • 增加的緩和選擇照護
  • 市場阻礙因素
    • 類鴉片物質的替代品的大麻的出現和合法化
    • 處方藥的濫用
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各產品類型
    • Codeine
    • Fentanyl
    • 嗎啡
    • Meperidine
    • 美沙酮
    • 其他
  • 各受體結合
    • 強力受體激動劑
    • 從輕度到中等度的受體激動劑
    • 混合受體反應
  • 各應用領域
    • 疼痛管理
    • 感冒和咳嗽
    • 腹瀉
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Allergan
  • Egalet Corporation
  • Endo Pharmaceuticals Inc.
  • Janssen Pharmaceuticals Inc.
  • Mallinckrodt
  • Pfizer Inc.
  • Purdue Pharma LP
  • Qrxpharma Limited
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd

第10章 市場未來展望

目錄
Product Code: 61713

The global opioids market was valued at approximately USD 19,869 million in 2020, and it is expected to reach USD 24,435 million in 2026 at a CAGR of 3.5% over the forecast period.

Globally, the COVID-19 pandemic showed many negative effects across the medical spectrum, which include a decrease in face-to-face appointments and an increase in telehealth visits. The COVID-19 pandemic also resulted in a period of isolation to maintain sufficient capacity in hospitals and to reduce the spread of the virus. Chronic pain was one of the hardest-hit fields from the COVID-19 pandemic, leaving many patients overburdened with their chronic pain and their ongoing treatment delayed. For instance, according to a research article by Rajendra K Sahoo et a., published in the Indian Journal of Anesthesia 2020, the study results found that 63.16% of pain physicians had a fear of spreading or contracting the disease to patient family members, 26.79% had impaired sleep, 1.43% physicians were feeling depressed, and 8.14% had feelings of anxiety.

Some of the other major factors driving the market growth include the increasing prevalence of diseases that cause chronic pain, such as cancer, arthritis, lower back pain, fibromyalgia and postsurgical pain, inclination toward extended-release formulations from the immediate release of opioids, and the rising focus on the abuse-deterrent formulation (ADF) by generic manufacturers.

Opioids are considered as most effective drugs for the management of pain. Moreover, their use in the management of chronic pain is considered to be standard practice in most parts of the world. Due to an increase in the burden of medical ailments, the Opioids market is expected to grow over the forecast period.

Furthermore, opioids play a key role in post-operative settings to provide adequate analgesia. As per the Center for Disease Control and Prevention 2020, over 32.5 million patients were affected by osteoarthritis in the United States. In the United Kingdom, there is a steadily increasing rate of osteoarthritis. As per Versus Arthritis, in 2019, it was estimated that over 18% of people who were above 45 years of age in England had osteoarthritis of the knee.

According to a research article by Eugenio Cavalli et a., published in the International Journal of Immunopathology and Pharmacology 2019, globally, the prevalence of neuropathic pain among the general population was estimated to be between 3%-17%. Therefore, opioid therapy is the mainstay of orthopedic treatment of patients with moderate to severe pain, and this helps to drives the overall growth of the market. However, factors such as the advent and legalization of cannabis as an alternative to opioids and prescription drug abuse are expected to impede market growth over the forecast period.

Key Market Trends

Strong Agonists are Expected to Hold Significant Market Share in the Receptor Binding Segment

An agonist is a drug molecule that triggers certain receptors in the brain. This agonist produces a significant physiological/pharmacological response when only a relatively small number of receptors are occupied, i.e., the drug has high intrinsic activity. Strong agonist opioids include fentanyl, morphine, dihydromorphinone, meperidine, oxycodone, and oxymorphone.

Globally, COVID-19 created a health crisis. During the COVID-19 pandemic, globally, health agencies were engaged in the prevention of infection and providing services to COVID-19 patients, leading to the cancellation of elective surgeries and elective consultations, which showed an effect on pain services by hospitals and pain clinics.

Methadone is a strong agonist that effectively treats addiction to opioid drugs (such as heroin). Strong agonists bind tightly to opioid receptors, which undergo significant conformational changes.

Globally, many people experience pain in their daily lives. For instance, as per the Chronic Pain Association of Canada (CPAC) 2019 report estimates, chronic pain patients were experiencing a decline in quality of life with increasing pain. Moreover, between 17-31% of people report chronic pain. 50% of hospitalized patients report acute pain of moderate to severe intensity. The annual direct medical costs for chronic pain management were between USD 10,000-14,000 per patient.

The market players adopt various strategies such as product approvals and developments to expand their product portfolio, expansions, collaborations, and mergers to increase market share. For instance, in November 2018, AcelRx Pharmaceuticals Inc. received the US FDA approval for DSUVIA (Dsuvia is an opioid analgesic drug approximately 5 to 10 times as potent as its parent drug, fentanyl, and 500 times as potent as morphine) for use in adults in certified medically supervised healthcare settings for the management of acute pain severe enough to require an opioid analgesic. Thus, the above-mentioned factors are expected to drive the segment growth in the near future.

North America Dominates the Market and is Expected to Continue to Dominate in the Forecast Period

The major factors driving the market growth in North America include the rising incidence of orthopedic diseases, growing prevalence of chronic diseases, such as cancer and diabetes and rise in disposable income and surge in geriatric population, and the presence of key market players in the region.

In the United States, the COVID-19 pandemic forced healthcare systems to redistribute healthcare resources toward COVID-19 dedicated sites and intensive care units. During the COVID-19 pandemic 2020, chronic pain services that were non-urgent and outpatient and elective interventional procedures were reduced or interrupted during the COVID-19 pandemic to reduce the risk of viral spread.

According to a research article by Filomena Puntillo et al., published in Best Practice and Research: Clinical Anesthesiology Journal 2020, chronic pain populations remain isolated with consequent social and psychological impact. The shutdown of pain services due to the lockdown imposed by the US government during the COVID-19 pandemic affected chronic pain management.

The population of cancer survivors in the United States is growing rapidly with the increasing number of cancer pain patients, which is boosting the market growth. For instance, according to a research article by Changchuan Jiang et al., published in JAMA Oncology Journal 2019, as per study results, among 4,526 cancer survivors, 1,648 subjects reported to have chronic pain and 768 subjects to have high-impact chronic pain (HICP), representing approximately 5.39 million and 2.51 million cancer survivors, respectively.

As per the government of Canada, in 2019, around 7.63 million people had chronic pain in the country. In Canada, chronic pain had significant impacts on mental and physical health, family and community life, and the economy, with the total direct and indirect cost of USD 38.3 to USD 40.4 billion in 2019.

Morphine and codeine are the most commonly prescribed opioids for cancer pain. In 2018, the United States Food and Drug Administration launched the 2018 Strategic Policy Roadmap, which aims at reducing the misuse and abuse of opioid drugs. Thus, the above-mentioned factors are expected to show significant market growth over the forecast period.

Competitive Landscape

The opioids market is fragmented and competitive. The market consists of several players. However, with the rising usage of opioids in medicines, more companies are trying to enter this market, especially in emerging markets. However, strict laws and stringent regulatory policies are deterring market penetration by small- and mid-sized companies. Some of the market players include Teva Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals Inc., Hikma Pharmaceuticals PLC, and Purdue Pharmaceuticals L.P.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Orthopedic Diseases and Chronic Pain
    • 4.2.2 Inclination toward Extended Release Formulations from Immediate Release of Opioids
    • 4.2.3 Rising Focus on Abuse-deterrent Formulation (ADF) by Generic Manufacturers
  • 4.3 Market Restraints
    • 4.3.1 Advent and Legalization of Cannabis as an Alternative to Opioids
    • 4.3.2 Prescription Drug Abuse
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Codeine
    • 5.1.2 Fentanyl
    • 5.1.3 Morphine
    • 5.1.4 Meperidine
    • 5.1.5 Methadone
    • 5.1.6 Other Product Types
  • 5.2 By Receptor Binding
    • 5.2.1 Strong Agonist
    • 5.2.2 Mild to Moderate Agonist
  • 5.3 By Application
    • 5.3.1 Pain Management
      • 5.3.1.1 Cancer Pain
      • 5.3.1.2 Neuropathic Pain
      • 5.3.1.3 Osteoarthritis Pain
      • 5.3.1.4 Other Pain Managements
    • 5.3.2 Cold and Cough
    • 5.3.3 Diarrhoea
    • 5.3.4 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States (by Product Type, Receptor Binding, and Application)
      • 5.4.1.2 Canada (by Product Type, Receptor Binding, and Application)
      • 5.4.1.3 Mexico (by Product Type, Receptor Binding, and Application)
    • 5.4.2 Europe
      • 5.4.2.1 Germany (by Product Type, Receptor Binding, and Application)
      • 5.4.2.2 United Kingdom (by Product Type, Receptor Binding, and Application)
      • 5.4.2.3 France (by Product Type, Receptor Binding, and Application)
      • 5.4.2.4 Italy (by Product Type, Receptor Binding, and Application)
      • 5.4.2.5 Spain (by Product Type, Receptor Binding, and Application)
      • 5.4.2.6 Rest of Europe (by Product Type, Receptor Binding, and Application)
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China (by Product Type, Receptor Binding, and Application)
      • 5.4.3.2 Japan (by Product Type, Receptor Binding, and Application)
      • 5.4.3.3 India (by Product Type, Receptor Binding, and Application)
      • 5.4.3.4 Australia (by Product Type, Receptor Binding, and Application)
      • 5.4.3.5 South Korea (by Product Type, Receptor Binding, and Application)
      • 5.4.3.6 Rest of Asia-Pacific (by Product Type, Receptor Binding, and Application)
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC (by Product Type, Receptor Binding, and Application)
      • 5.4.4.2 South Africa (by Product Type, Receptor Binding, and Application)
      • 5.4.4.3 Rest of Middle-East and Africa (by Product Type, Receptor Binding, and Application)
    • 5.4.5 South America
      • 5.4.5.1 Brazil (by Product Type, Receptor Binding, and Application)
      • 5.4.5.2 Argentina (by Product Type, Receptor Binding, and Application)
      • 5.4.5.3 Rest of South America (by Product Type, Receptor Binding, and Application)

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Mallinckrodt Pharmaceuticals LLC
    • 6.1.2 Purdue Pharmaceuticals L.P.
    • 6.1.3 Rhodes Technologies LP
    • 6.1.4 Sun Pharmaceutical Industries Ltd
    • 6.1.5 Teva Pharmaceuticals Inc.
    • 6.1.6 Vertice Pharma LLC
    • 6.1.7 Johnson and Johnson
    • 6.1.8 AbbVie Inc (Allergan PLC)
    • 6.1.9 Hikma Pharmaceuticals PLC
    • 6.1.10 Endo Pharmaceuticals Inc.
    • 6.1.11 Zyla Life Sciences (Egalet Corporation)
    • 6.1.12 Amneal Pharmaceuticals Inc.
    • 6.1.13 Pfizer Inc.
    • 6.1.14 AcelRx Pharmaceuticals Inc
    • 6.1.15 Archimedes Pharma
    • 6.1.16 Cadila Healthcare (Sentynl Therapeutics Inc.)
    • 6.1.17 Alcaliber SA
    • 6.1.18 Verve Health Care Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS